Boston Scientific Hopes New Data Will Expand Boundaries Of DES Population
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific expects the new data from two trials released at the Transcatheter Cardiovascular Therapeutics Scientific Symposium in Washington, D.C., last week will encourage physicians to reconsider drug-eluting stents for a broader range of patients
You may also be interested in...
New Products In Brief
Boston Scientific becomes the first with drug-eluting stents that are FDA-approved for use in patients experiencing a heart attack. More product news.
American College Of Cardiology Conference In Brief
Remote monitoring speed: The Medtronic-funded CONNECT study, presented March 15 at the American College of Cardiology annual conference in Atlanta, identified a significant reduction in the time from onset of a device event to a clinical decision with the use of remote monitoring to track implantable defibrillator and cardiac resynchronization therapy defibrillator events. The median time to decision was 4.6 days in the remotely monitored group compared to 22 days for patients that relied only on office visits. Remotely monitored patients also had fewer office visits and shorter hospitalizations
American College Of Cardiology Conference In Brief
Remote monitoring speed: The Medtronic-funded CONNECT study, presented March 15 at the American College of Cardiology annual conference in Atlanta, identified a significant reduction in the time from onset of a device event to a clinical decision with the use of remote monitoring to track implantable defibrillator and cardiac resynchronization therapy defibrillator events. The median time to decision was 4.6 days in the remotely monitored group compared to 22 days for patients that relied only on office visits. Remotely monitored patients also had fewer office visits and shorter hospitalizations